首页> 外文期刊>Journal of Internal Medicine >Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies.
【24h】

Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies.

机译:载脂蛋白B,载脂蛋白AI,载脂蛋白B / AI比率与冠心病之间的关联:基于文献的前瞻性荟萃分析。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: To assess associations of circulating levels of apolipoprotein (apo) AI, apoB and the apoB/AI ratio (apoB/A) with risk of incident coronary heart disease (CHD). DESIGN: Literature-based meta-analysis of prospective studies. DATA SOURCES: Prospective studies in essentially general populations that reported on associations between apoAI, apoB or apoB/A and first incident CHD outcomes. Studies were identified by computer-based searches and by manual searches of the relevant literature. RESULTS: Data from 23 relevant studies were identified. For apoAI, with 6333 CHD cases in 21 studies, comparison of individuals in the bottom third with those in the top third of baseline values yielded a combined relative risk of 1.62 (95% confidence interval: 1.43-1.83), i.e. an inverse association. For apoB, a combined analysis of 6320 CHD cases from 19 studies gave a relative risk of 1.99 (1.65-2.39) for a comparison of individuals in the top third versus those in the bottom third of baseline values. For apoB/A, with 3730 CHD cases from seven studies, a comparison of individuals in the top third versus the bottom third of baseline values gave a combined relative risk of 1.86 (1.55-2.22). These associations were somewhat stronger following correction for within-person variations in apolipoprotein levels. There was evidence of heterogeneity amongst the published studies, but it was only partly explained by available study-level characteristics. CONCLUSIONS: The present quantitative review suggests the existence of moderately strong associations between baseline levels of each of apoAI, apoB, and apoB/A and risk of CHD. More detailed analysis, perhaps based on individual participant data from prospective studies, could help to overcome several limitations in the present review and to clarify any relevance of these apolipoproteins to disease prediction and aetiology.
机译:目的:评估载脂蛋白(apo)AI,apoB和apoB / AI比率(apoB / A)的循环水平与发生冠心病(CHD)的风险之间的关系。设计:基于文献的前瞻性研究荟萃分析。数据来源:前瞻性研究主要针对一般人群,这些人群报告了apoAI,apoB或apoB / A与首次发生冠心病的预后之间的关联。通过计算机检索和相关文献的人工检索来鉴定研究。结果:确定了来自23项相关研究的数据。对于apoAI,在21个研究中有6333例CHD病例,比较基线值底部三分之一和顶部三分之一的个体产生的相对危险度为1.62(95%置信区间:1.43-1.83),即呈负相关。对于apoB,来自19个研究的6320个CHD病例的综合分析得出的基线值的前三分之一与后三分之一的个人相对风险为1.99(1.65-2.39)。对于apoB / A,来自七项研究的3730例CHD病例,比较基线值的前三分之一与后三分之一的个体的相对相对危险度为1.86(1.55-2.22)。在校正人体内载脂蛋白水平的变化后,这些关联性在某种程度上更强。在已发表的研究中有异质性的证据,但是可用研究水平的特征仅部分解释了这一点。结论:本定量研究表明,apoAI,apoB和apoB / A的基线水平与冠心病风险之间存在中等程度的强关联。可能基于前瞻性研究的个体参与者数据进行更详细的分析,可能有助于克服本综述中的一些局限性,并阐明这些载脂蛋白与疾病预测和病因学的相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号